


consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

The preferred indications using the compounds of the present disclosure are depression, psychosis, Parkinson's disease, anxiety and attention deficit hyperactivity disorder (ADHD) and

5 diabetes.

In a first aspect, there is provided a compound of formula




wherein

- R^1 is phenyl, optionally substituted by halogen, ~~C₁₋₇-lower~~alkyl, ~~C₃₋₆-lower~~ cycloalkyl, ~~C₁₋₇-lower~~alkoxy, cyano, ~~C₁₋₇-lower~~alkyl substituted by halogen, ~~C₁₋₇-lower~~alkyl substituted by hydroxy, ~~C₁₋₇-lower~~alkoxy substituted by halogen or ~~C₁₋₇-lower~~alkoxy substituted by hydroxy; or is
- 10 pyridine-2, 3 or 4-yl, optionally substituted by halogen, ~~C₁₋₇-lower~~alkyl, ~~C₃₋₆-lower~~cycloalkyl, cyano, ~~C₁₋₇-lower~~alkyl substituted by halogen, ~~C₁₋₇-lower~~alkyl substituted by hydroxyl, ~~C₁₋₇-lower~~alkoxy, ~~C₁₋₇-lower~~alkoxy substituted by halogen, or ~~C₁₋₇-lower~~alkoxy substituted by hydroxyl; or is
- 15 pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, ~~C₁₋₇-lower~~alkyl, ~~C₃₋₆-lower~~cycloalkyl, ~~C₁₋₇-lower~~alkyl substituted by hydroxy or ~~C₁₋₇-lower~~alkyl substituted by halogen, or is pyrazin-2-yl, optionally substituted by halogen, ~~C₁₋₇-lower~~alkyl, ~~C₃₋₆-lower~~cycloalkyl, ~~C₁₋₇-lower~~alkyl substituted by halogen, ~~C₁₋₇-lower~~alkyl substituted by hydroxy or cyano, or is
- 20 2,2-difluorobenzo[d][1,3]dioxol-5-yl, or is thiazolyl, optionally substituted by ~~C₁₋₇-lower~~alkyl substituted by halogen;
- R^2 is hydrogen or ~~C₁₋₇-lower~~alkyl;
- R^3 is hydrogen, amino or ~~C₁₋₇-lower~~alkyl;
- 25 Z is a bond, -CH₂- or -O-;
- or a pharmaceutically suitable acid addition salt thereof.

Claims


1. A compound of formula



wherein

- 5 R^1 is phenyl, optionally substituted by halogen, ~~lower C₁₋₇-alkyl~~, ~~lower C₃₋₆-cycloalkyl~~,
~~lower C₁₋₇-alkoxy~~, cyano, ~~lower C₁₋₇-alkyl~~ substituted by halogen, ~~lower C₁₋₇-alkyl~~
substituted by hydroxy, ~~lower C₁₋₇-alkoxy~~ substituted by halogen or ~~lower C₁₋₇-alkoxy~~
substituted by hydroxy; or is
pyridine-2, 3 or 4-yl, optionally substituted by halogen, ~~lower C₁₋₇-alkyl~~, ~~lower C₃₋₆-~~
10 ~~cycloalkyl~~, cyano, ~~lower C₁₋₇-alkyl~~ substituted by halogen, ~~lower C₁₋₇-alkyl~~ substituted by
hydroxyl, ~~lower C₁₋₇-alkoxy~~, ~~lower C₁₋₇-alkoxy~~ substituted by halogen, or ~~lower C₁₋₇-~~
~~alkoxy~~ substituted by hydroxyl; or is
pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, ~~lower C₁₋₇-alkyl~~, ~~lower C₃₋₆-~~
15 ~~cycloalkyl~~, ~~lower C₁₋₇-alkyl~~ substituted by hydroxy or ~~lower C₁₋₇-alkyl~~ substituted by
halogen, or is
pyrazin-2-yl, optionally substituted by halogen, ~~lower C₁₋₇-alkyl~~, ~~lower C₃₋₆-cycloalkyl~~,
~~lower C₁₋₇-alkyl~~ substituted by halogen, ~~lower C₁₋₇-alkyl~~ substituted by hydroxy or
cyano, or is
2,2-difluorobenzo[d][1,3]dioxol-5-yl, or is
20 thiazolyl, optionally substituted by ~~lower C₁₋₇-alkyl~~ substituted by halogen;
- R^2 is hydrogen or ~~lower C₁₋₇-alkyl~~;
- R^3 is hydrogen, amino or ~~lower C₁₋₇-alkyl~~;
- Z is a bond, -CH₂- or -O-;
- or a pharmaceutically suitable acid addition salt thereof.

25 2. A compound of formula IA according to claim 1,



IA

wherein

R^2 is hydrogen or lower-C₁₋₇-alkyl;

R^3 is hydrogen, amino or lower-C₁₋₇-alkyl;

5 R^4 is hydrogen, halogen, lower-C₁₋₇-alkyl, lower-C₃₋₆-cycloalkyl, lower-C₁₋₇-alkoxy, cyano, lower-C₁₋₇-alkyl substituted by halogen, lower-C₁₋₇-alkyl substituted by hydroxyl, lower-C₁₋₇-alkoxy substituted by halogen or lower-C₁₋₇-alkoxy substituted by hydroxy;

n is 1 or 2

Z is a bond, -CH₂- or -O-;

10 or a pharmaceutically suitable acid addition salt thereof.

3. A compound according to any one of claims 1 or 2, wherein the compounds are

(S)-5-methyl-N-(4-(morpholin-2-yl)phenyl)-1-phenyl-1H-pyrazole-4-carboxamide

(S)-5-amino-1-(4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-methoxyphenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

15 (S)-1-(4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-cyanophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(R)-1-(4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-cyanophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

20 (S)-1-(4-bromo-2-cyanophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-(difluoromethoxy)phenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-(difluoromethoxy)phenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-cyano-2-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-cyano-3-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

25 (S)-1-(2-cyano-4-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazole-4-carboxamide

(R)-1-(4-(difluoromethoxy)phenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-(difluoromethoxy)phenyl)-5-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(4-(difluoromethoxy)phenyl)-3-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide


(S)-1-(4-cyanophenyl)-5-methyl-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(R)-1-(4-cyano-2-fluorophenyl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide


(RS)-1-(4-difluoromethoxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-pyrrolidin-3-yl-phenyl)-amide or

(RS)-1-(4-difluoromethoxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-piperidin-3-yl-phenyl)-amide.

4. A compound of formula IB according to claim 1,



wherein



15 is pyridine-2, 3 or 4-yl;


R^2 is hydrogen or lower C₁₋₇-alkyl;

R^3 is hydrogen, amino or lower C₁₋₇-alkyl;

R^5 is hydrogen, halogen, lower C₁₋₇-alkyl, lower C₃₋₆-cycloalkyl, cyano, lower C₁₋₇-alkyl substituted by halogen, lower C₁₋₇-alkyl substituted by hydroxy, lower C₁₋₇-alkoxy, lower C₁₋₇-alkoxy substituted by halogen, lower C₁₋₇-alkoxy substituted by hydroxy;

n is 1 or 2;

Z is a bond, -CH₂- or -O-;



wherein

R^2 is hydrogen or lower C₁₋₇-alkyl;

5 R^3 is hydrogen, amino or lower C₁₋₇-alkyl;

R^6 is hydrogen, halogen, lower C₁₋₇-alkyl, lower C₃₋₆-cycloalkyl, C₁₋₇-lower-alkyl substituted by halogen or lower C₁₋₇-alkyl substituted by hydroxy;

Z is a bond, -CH₂- or -O-;

or a pharmaceutically suitable acid addition salt thereof.

10

7. A compound according to any one of claims 1 or 6, wherein the compounds are
(S)-1-(5-chloropyrimidin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide
(S)-N-(4-(morpholin-2-yl)phenyl)-1-(2-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazole-4-
carboxamide

15 (S)-1-(2-chloropyrimidin-4-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide
(S)-N-(4-(morpholin-2-yl)phenyl)-1-(5-(trifluoromethyl)pyrimidin-2-yl)-1H-pyrazole-4-
carboxamide

(S)-1-(4-methylpyrimidin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(6-(trifluoromethyl)pyrimidin-4-yl)-1H-pyrazole-4-


20 carboxamide

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(2-(trifluoromethyl)pyrimidin-5-yl)-1H-pyrazole-4-carboxamide or

(S)-N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethyl)pyrimidin-2-yl)-1H-pyrazole-4-carboxamide.

5 (S)-1-(6-cyclopropylpyrimidin-4-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide.

8. A compound of formulas ID according to claim 1,



wherein

10 R^2 is hydrogen or ~~lower~~ C₁₋₇-alkyl;

R^3 is hydrogen, amino or ~~lower~~ C₁₋₇-alkyl;

R^7 is hydrogen, halogen, ~~lower~~ C₁₋₇-alkyl, ~~lower~~ C₃₋₆-cycloalkyl, C₁₋₇-~~lower~~ alkyl substituted by halogen, ~~lower~~ C₁₋₇-alkyl substituted by hydroxyl or cyano;

Z is a bond, -CH₂- or -O-;

15 or a pharmaceutically suitable acid addition salt thereof.

9. A compound according to any one of claims 1 or 8, wherein the compounds are (S)-N-(4-(morpholin-2-yl)phenyl)-1-(6-(trifluoromethyl)pyrazin-2-yl)-1H-pyrazole-4-carboxamide

20 (S)-1-(6-methylpyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(5-methylpyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-chloropyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide


(S)-1-(5-cyanopyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(5-chloropyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

25 (S)-1-(6-cyanopyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide

(S)-1-(3-cyanopyrazin-2-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-carboxamide or (S)-N-(4-(morpholin-2-yl)phenyl)-1-(5-(trifluoromethyl)pyrazin-2-yl)-1H-pyrazole-4-carboxamide.

5 10. A compound of formulas IE according to claim 1,



wherein

R^2 is hydrogen or lower C₁₋₇-alkyl;

R^3 is hydrogen, amino or lower C₁₋₇-alkyl;


10 Z is a bond, -CH₂- or -O-;

or a pharmaceutically suitable acid addition salt thereof.

11. A compound according to any one of claims 1 or 10, wherein the compound is (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(4-(morpholin-2-yl)phenyl)-1H-pyrazole-4-

15 carboxamide.

12. A compound of formula IF according to claim 1



wherein

20 R^2 is hydrogen or lower C₁₋₇-alkyl;


R^3 is hydrogen, amino or lower ~~C₁₋₇~~-alkyl

Z is a bond, -CH₂- or -O-;


or a pharmaceutically suitable acid addition salt thereof.

5 13. A compound according to any one of claims 1 or 12, wherein the compound is (S)-N-(4-(morpholin-2-yl)phenyl)-1-(4-(trifluoromethyl)thiazol-2-yl)-1H-pyrazole-4-carboxamide.

10 14. A process for the manufacture of a compound of formula I according to any one of claims 1 - 13, which process comprises cleaving off the protecting group of compounds of formula



to form a compound of formula I



15 and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts, wherein the substituents are as described in claim 1.

15. A compound according to any one of claims 1 -13, when manufactured by a process according to claim 14.